Pharmacoeconomic analysis of dapagliflozin in patients with chronic kidney disease and type 2 diabetes in the Russian Federation

• المؤلفون الرئيسيون: Sergey V. Nedogoda (مؤلف), Minara S. Shamkhalova (مؤلف), Alla S. Salasyuk (مؤلف), Viktoriya O. Lutova (مؤلف), Irina N. Barykina (مؤلف), Ekaterina A. Popova (مؤلف)
• التنسيق: كتاب
• منشور في: LLC "MEDIAFORMAT", 2024-02-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Background. The economic costs associated with chronic kidney disease (CKD) are a significant burden on the health care system. The use of dapagliflozin is a breakthrough strategy in the management of patients with CKD and type 2 diabetes mellitus (T2DM) to slow the progression of the disease and re...